SM 88

Drug Profile

SM 88

Alternative Names: SM-88

Latest Information Update: 13 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tyme Technologies
  • Developer The Joseph Ahmed Foundation; Tyme Technologies
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Free radical stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer; Prostate cancer
  • Clinical Phase Unknown Ewing's sarcoma
  • Preclinical Breast cancer; Cancer; Glioma; Osteosarcoma

Most Recent Events

  • 10 Oct 2018 Tyme Technologies and PanCAN plan the phase II/III Precision Promise trial for Pancreatic cancer (Monotherapy, First-line therapy or greater, Combination therapy) in USA in the first half of 2019
  • 27 Sep 2018 Tyme Technologies in collaboration with The Joseph Ahmed Foundation (JAF) plans a phase II trial for Ewing’s sarcoma (Metastatic disease, Second-line therapy or greater) in USA in the first quarter of 2019
  • 01 Aug 2018 Tyme Technologies plans a phase II extension trial to evaluate the long term safety and efficacy of SM 88 in Prostate cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top